Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis

Tien Tang; Sally Abbott; Carel W le Roux; Violet Wilson; Rishi Singhal; Srikanth Bellary; Abd Tahrani

doi:10.1111/dom.13131

Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis

Tien Tang, Sally Abbott, Carel W le Roux, Violet Wilson, Rishi Singhal, Srikanth Bellary, Abd Tahrani

Research output: Contribution to journal › Article › peer-review

Abstract

We examined the relationship between weight changes following preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) and weight changes from the start of medical weight management (MWM) till 12 months after bariatric surgery in patients with Type 2 diabetes in a retrospective cohort study. Forty-five patients (64.4% women, median age 49 (IQR 45-60) years) were included. The median weight loss from start of MWM until 12 months post-surgery was 17.9% (13.0%-29.3%). GLP-1 RA during MWM resulted in 5.0% (1.9%-7.7%) weight loss. Weight loss during GLP-1 RA treatment predicted weight loss from the start of MWM till 12 months post-surgery; but not post-operative weight loss following adjustment. The proportion of weight loss from start of MWM to 12 months post-surgery attributed to GLP-1 RA was negatively associated with that attributed to surgery following adjustment. In conclusion, weight change following GLP-1 RA predicted the weight loss achieved by a combination of MWM and bariatric surgery, but not weight loss induced by surgery only. Failure to lose weight following GLP-1 RA should not be considered a barrier to having bariatric surgery.

Original language	English
Pages (from-to)	745-748
Journal	Diabetes, Obesity and Metabolism
Volume	20
Issue number	3
Early online date	22 Nov 2017
DOIs	https://doi.org/10.1111/dom.13131
Publication status	Published - 13 Feb 2018

Bibliographical note

This is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon‐like peptide‐1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2018;20:745–748, which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

Keywords

bariatric surgery
glucagon-like peptide-1 receptor agonist
aparoscopic adjustable gastric band
laparoscopic sleeve gastrectomy
obesity
Roux-en-Y gastric bypass
type 2 diabetes mellitus
weight loss

Access to Document

10.1111/dom.13131

Preoperative Weight Loss with GLP-1
This is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon‐like peptide‐1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2018;20:745–748, which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Accepted author manuscript, 59.1 KB

Fingerprint

Dive into the research topics of 'Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis'. Together they form a unique fingerprint.

Cite this

Tang, T., Abbott, S., le Roux, C. W., Wilson, V., Singhal, R., Bellary, S., & Tahrani, A. (2018). Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis. Diabetes, Obesity and Metabolism, 20(3), 745-748. https://doi.org/10.1111/dom.13131

@article{acebc1c576474cfebf579259be64d663,

title = "Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis",

abstract = "We examined the relationship between weight changes following preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) and weight changes from the start of medical weight management (MWM) till 12 months after bariatric surgery in patients with Type 2 diabetes in a retrospective cohort study. Forty-five patients (64.4% women, median age 49 (IQR 45-60) years) were included. The median weight loss from start of MWM until 12 months post-surgery was 17.9% (13.0%-29.3%). GLP-1 RA during MWM resulted in 5.0% (1.9%-7.7%) weight loss. Weight loss during GLP-1 RA treatment predicted weight loss from the start of MWM till 12 months post-surgery; but not post-operative weight loss following adjustment. The proportion of weight loss from start of MWM to 12 months post-surgery attributed to GLP-1 RA was negatively associated with that attributed to surgery following adjustment. In conclusion, weight change following GLP-1 RA predicted the weight loss achieved by a combination of MWM and bariatric surgery, but not weight loss induced by surgery only. Failure to lose weight following GLP-1 RA should not be considered a barrier to having bariatric surgery.",

keywords = "bariatric surgery, glucagon-like peptide-1 receptor agonist, aparoscopic adjustable gastric band, laparoscopic sleeve gastrectomy, obesity, Roux-en-Y gastric bypass, type 2 diabetes mellitus, weight loss",

author = "Tien Tang and Sally Abbott and {le Roux}, {Carel W} and Violet Wilson and Rishi Singhal and Srikanth Bellary and Abd Tahrani",

note = "This is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon‐like peptide‐1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2018;20:745–748, which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.",

year = "2018",

month = feb,

day = "13",

doi = "10.1111/dom.13131",

language = "English",

volume = "20",

pages = "745--748",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "3",

}

Tang, T, Abbott, S, le Roux, CW, Wilson, V, Singhal, R, Bellary, S & Tahrani, A 2018, 'Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis', Diabetes, Obesity and Metabolism, vol. 20, no. 3, pp. 745-748. https://doi.org/10.1111/dom.13131

Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis. / Tang, Tien; Abbott, Sally; le Roux, Carel W et al.
In: Diabetes, Obesity and Metabolism, Vol. 20, No. 3, 13.02.2018, p. 745-748.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes

T2 - A Longitudinal Analysis

AU - Tang, Tien

AU - Abbott, Sally

AU - le Roux, Carel W

AU - Wilson, Violet

AU - Singhal, Rishi

AU - Bellary, Srikanth

AU - Tahrani, Abd

N1 - This is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon‐like peptide‐1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2018;20:745–748, which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

PY - 2018/2/13

Y1 - 2018/2/13

N2 - We examined the relationship between weight changes following preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) and weight changes from the start of medical weight management (MWM) till 12 months after bariatric surgery in patients with Type 2 diabetes in a retrospective cohort study. Forty-five patients (64.4% women, median age 49 (IQR 45-60) years) were included. The median weight loss from start of MWM until 12 months post-surgery was 17.9% (13.0%-29.3%). GLP-1 RA during MWM resulted in 5.0% (1.9%-7.7%) weight loss. Weight loss during GLP-1 RA treatment predicted weight loss from the start of MWM till 12 months post-surgery; but not post-operative weight loss following adjustment. The proportion of weight loss from start of MWM to 12 months post-surgery attributed to GLP-1 RA was negatively associated with that attributed to surgery following adjustment. In conclusion, weight change following GLP-1 RA predicted the weight loss achieved by a combination of MWM and bariatric surgery, but not weight loss induced by surgery only. Failure to lose weight following GLP-1 RA should not be considered a barrier to having bariatric surgery.

AB - We examined the relationship between weight changes following preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) and weight changes from the start of medical weight management (MWM) till 12 months after bariatric surgery in patients with Type 2 diabetes in a retrospective cohort study. Forty-five patients (64.4% women, median age 49 (IQR 45-60) years) were included. The median weight loss from start of MWM until 12 months post-surgery was 17.9% (13.0%-29.3%). GLP-1 RA during MWM resulted in 5.0% (1.9%-7.7%) weight loss. Weight loss during GLP-1 RA treatment predicted weight loss from the start of MWM till 12 months post-surgery; but not post-operative weight loss following adjustment. The proportion of weight loss from start of MWM to 12 months post-surgery attributed to GLP-1 RA was negatively associated with that attributed to surgery following adjustment. In conclusion, weight change following GLP-1 RA predicted the weight loss achieved by a combination of MWM and bariatric surgery, but not weight loss induced by surgery only. Failure to lose weight following GLP-1 RA should not be considered a barrier to having bariatric surgery.

KW - bariatric surgery

KW - glucagon-like peptide-1 receptor agonist

KW - aparoscopic adjustable gastric band

KW - laparoscopic sleeve gastrectomy

KW - obesity

KW - Roux-en-Y gastric bypass

KW - type 2 diabetes mellitus

KW - weight loss

UR - https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13131

U2 - 10.1111/dom.13131

DO - 10.1111/dom.13131

M3 - Article

C2 - 29053203

SN - 1462-8902

VL - 20

SP - 745

EP - 748

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 3

ER -

Tang T, Abbott S, le Roux CW, Wilson V, Singhal R, Bellary S et al. Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis. Diabetes, Obesity and Metabolism. 2018 Feb 13;20(3):745-748. Epub 2017 Nov 22. doi: 10.1111/dom.13131

Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this